Assessing Mycobacterium vaccae with Chemotherapy in Mesothelioma Patients
Author Information
Author(s): Mendes R, O'Brien M E R, Mitra A, Norton A, Gregory R K, Padhani A R, Bromelow K V, Winkley A R, Ashley S, Smith I E, Souberbielle B E
Primary Institution: The Royal Marsden Hospital NHS Trust
Hypothesis
Can intratumoural/intrapleural SRL172 combined with standard chemotherapy improve outcomes in patients with malignant mesothelioma?
Conclusion
SRL172 can be safely administered in combination with chemotherapy, showing a partial response rate of 37.5% in patients with malignant mesothelioma.
Supporting Evidence
- There were six out of 16 partial responses (37.5%) observed.
- Patients showed an increase in activated natural killer cells post-treatment.
- The study established a safe dose for future phase II testing.
Takeaway
This study tested a new treatment for a type of lung cancer called mesothelioma, and it found that adding a special vaccine to regular chemotherapy can help some patients feel better.
Methodology
Patients received standard chemotherapy along with intratumoural/intrapleural SRL172 injections, and were assessed for toxicity and response through imaging and blood tests.
Potential Biases
Potential bias due to the small number of patients and the nature of the treatment being tested.
Limitations
The study had a small sample size and was limited to patients with advanced disease.
Participant Demographics
Mean age 62 years, 12 males and 4 females, with a majority having epithelial mesothelioma.
Statistical Information
P-Value
0.02
Statistical Significance
p=0.02
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website